Yesterday was World Colorectal Cancer Day, the most frequent tumor in the Spanish Population and the second cause of cancer death worldwide, leading to almost 1 million deaths per year. In 2020, almost 2 million cases were diagnosed. Aniling is aware of the impact of colorectal cancer (CRC) in society and the importance of early screening to reduce the number of deaths and improve the patient journey.
Aniling aims to improve early CRC detection and treatment by developing two new products: GEUS-LB, which aims to detect colorectal cancer from liquid biopsy samples, and GEUS-CRC, focused on analyzing colorectal biopsies in order to select the best treatment for the patient. Both products are based on Aniling’s patented GEUS technology that integrates into a single test genetics and epigenetics.